Fri Sep 06 15:56:54 UTC 2024: 1. Title: “COVID-19 vaccine developers Pfizer and BioNTech conclude Phase 3 trial, report 95% efficacy”

2. Pfizer and BioNTech announced the completion of their Phase 3 clinical trial for their COVID-19 vaccine candidate.

3. The vaccine was reported to have an efficacy rate of 95% in preventing COVID-19 infection among participants.

4. The companies plan to seek emergency use authorization from the FDA in the coming weeks.

5. The vaccine was found to be consistent across different age groups, races, and ethnicities.

6. Pfizer and BioNTech expect to produce up to 1.3 billion doses of the vaccine in 2021.

7. This news marks a significant milestone in the race to develop a safe and effective vaccine against COVID-19.

Read More